RRC ID 18898
Author Tsuchiya K, Hida K, Hida Y, Muraki C, Ohga N, Akino T, Kondo T, Miseki T, Nakagawa K, Shindoh M, Harabayashi T, Shinohara N, Nonomura K, Kobayashi M.
Title Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization.
Journal Int. J. Oncol.
Abstract Adrenomedullin (AM) is a multifunctional 52-amino acid peptide. AM has several effects and acts as a growth factor in several types of cancer cells. Our previous study revealed that an AM antagonist (AMA) suppressed the growth of pancreatic tumors in mice, although its mechanism was not elucidated. In this study, we constructed an AMA expression vector and used it to treat renal cell carcinoma (RCC) in mice. This AMA expression vector significantly reduced tumor growth in mice. In addition, microvessel density was decreased in AMA-treated tumors. To analyze the effect of AMA on tumor angiogenesis in this model, tumor endothelial cells (TECs) were isolated from RCC xenografts. TEC proliferation was stimulated by AM and it was inhibited by AMA significantly. AM induced migration of TECs and it was also blocked by AMA. However, normal ECs (NECs) were not affected by either AM or AMA. These results demonstrate that AMA has inhibitory effects on TECs specifically, not on NEC, thereby inhibiting tumor angiogenesis. Furthermore, we showed that vascular endothelial growth factor-induced mobilization of endothelial progenitor cell (EPC) into circulation was inhibited by AMA. These results suggest that AMA can be considered a good anti-angiogenic reagent that selectively targets TECs and EPC in renal cancer.
Volume 36(6)
Pages 1379-86
Published 2010-6
DOI 10.3892/ijo_00000622
PMID 20428760
MeSH Adrenomedullin / antagonists & inhibitors* Animals Antineoplastic Agents / therapeutic use* Carcinoma, Renal Cell / blood supply Carcinoma, Renal Cell / therapy* Cell Line, Tumor Cell Proliferation DNA / therapeutic use* Endothelial Cells / metabolism Endothelial Cells / pathology Female Genetic Therapy / methods* Humans Immunohistochemistry Kidney Neoplasms / blood supply Kidney Neoplasms / therapy* Mice Mice, Nude Neovascularization, Pathologic / therapy Reverse Transcriptase Polymerase Chain Reaction Stem Cells / cytology Stem Cells / metabolism Xenograft Model Antitumor Assays
IF 3.333
Times Cited 25
WOS Category ONCOLOGY
Resource
Human and Animal Cells OS-RC-2 (RCB0735)